The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8478-8491

  Wang, Jiabei ^a   Yin, Dalong ^a   Xie, Changming ^a   Zheng, Tongsen ^a   Liang, Yingjian ^a   Hong, Xuehui ^a   Lu, Zhaoyang ^a   Song, Xuan ^a   Song, Ruipeng ^a   Yang, Haiyan ^a   Sun, Boshi ^a   Bhatta, Nishant ^a   Meng, Xianzhi ^a   Pan, Shangha ^a   Jiang, Hongchi ^a   Liu, Lianxin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Dp44mT; Hepatocellular carcinoma; Metastasis; NDRG2; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CLAUDIN 1; CLAUDIN 8; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 8; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; GELATINASE A; GLYCOPROTEIN GP 130; GOOSECOID PROTEIN; JAGGED1; JAGGED2; N MYC DOWNSTREAM REGULATED GENE 2 PROTEIN; NERVE CELL ADHESION MOLECULE; PEPTIDES AND PROTEINS; SMAD3 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; IRON CHELATING AGENT; MESSENGER RNA; NDRG2 PROTEIN; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; IL6ST PROTEIN, HUMAN; NDRG2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; THIOSEMICARBAZONE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CELL ADHESION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL TISSUE; GENE SILENCING; LIVER CANCER CELL LINE; METASTASIS INHIBITION; OVERALL SURVIVAL; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SECONDARY; TIME; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CYTOKINE RECEPTOR GP130; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IRON CHELATING AGENTS; LIVER NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIOSEMICARBAZONES; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908010561     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2328     Document Type: Article

References (42)

1. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ and Whelton PK. Major causes of death among men and women in China. N Engl J Med. 2005; 353(11):1124-1134.
2. El-Serag HB, Marrero JA, Rudolph L and Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6):1752-1763.
3. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-235.
4. Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH, Chen Y and Wang Z. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013; 4(11):1999-2009.
5. Kalinowski DS and Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57(4):547-583.
6. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med. 1996; 20(4):553-566.
7. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev. 1996; 5(1):19-36.
8. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009; 100(1):9-16.
9. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK and Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008; 100(14):996-1002.
10. Wu T, Sempos CT, Freudenheim JL, Muti P and Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol. 2004; 14(3):195-201.
11. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y and Shacter EB. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009; 69(3):948-957.
12. Richardson D, Ponka P and Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994; 54(3):685-689.
13. Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol. 1997; 75(10-11):1164-1180.
14. Whitnall M, Howard J, Ponka P and Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103(40):14901-14906.
15. Yuan J, Lovejoy DB and Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104(5):1450-1458.
16. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR and Egwuagu CE. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene. 2007; 26(13):1941-1948.
17. Oh SS, Kim D, Kim DH, Chang HH, Sohn KC, Kim KH, Jung SH, Lee BK, Kim JH and Kim KD. NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-beta production. Carcinogenesis. 2012; 33(10):1882-1888.
18. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI and Lim JS. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis. 2009; 30(6):927-936.
19. Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Yang A, Han H and Yao L. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007; 358(1):164-169.
20. Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, D'Addabbo A, Ancona N, Fusilli S, Perri F and Andriulli A. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics. 2009; 2:11.
21. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G and Riemenschneider MJ. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008; 123(9):2080-2086.
22. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH and Perry A. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005; 65(16):7121-7126.
23. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, Kim JW, Song EY, Kim DM, Lee MN, Oh GT, Kim SJ, et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res. 2008; 68(11):4210-4220.
24. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(4):187-196.
25. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK and Tang ZY. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004; 130(8):460-468.
26. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O and Antonaci S. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine. 2000; 12(6):811-814.
27. Oft M, Heider KH and Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998; 8(23):1243-1252.
28. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T and Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001; 91(5):964-971.
29. Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren ZG, Sun HC and Tang ZY. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res. 2010; 16(10):2740-2750.
30. Kijima H, Sawada T, Tomosugi N and Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer. 2008; 8:167.
31. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE and Hui KM. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood). 2009; 234(6):693-702.
32. Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL and Yu HS. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol. 2009; 135(10):1413-1420.
33. Yamasaki T, Terai S and Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med. 2011; 365(6):576-578.
34. Ba Q, Hao M, Huang H, Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, Chen K, Liu H and Wang H. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res. 2011; 17(24):7625-7633.
35. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M and Bernhardt PV. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem. 2006; 49(22):6510-6521.
36. Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X and Yao LB. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 2004; 10(23):3518-3521.
37. Bianchi FB, Biagini G, Ballardini G, Cenacchi G, Faccani A, Pisi E, Laschi R, Liotta L and Garbisa S. Basement membrane production by hepatocytes in chronic liver disease. Hepatology. 1984; 4(6):1167-1172.
38. Shon SK, Kim A, Kim JY, Kim KI, Yang Y and Lim JS. Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun. 2009; 385(2):198-203.
39. Kamran MZ, Patil P and Gude RP. Role of STAT3 in Cancer Metastasis and Translational Advances. Biomed Res Int. 2013; 2013:421821.
40. Huang S and Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010; 9(3):742-750.
41. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG and Zhang H. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res. 2006; 12(23):7140-7148.
42. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J and Liu L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology. 2013; 57(5):1847-1857.